Itraconazol Ratiopharm

Itraconazole, the active ingredient in Itraconazol Ratiopharm, is a triazole antifungal presented as an oral dosage form for oral use. It treats systemic and localized fungal infections in adults and children as prescribed.

GNH USA supplies Itraconazol Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Itraconazole is used to manage fungal infections by targeting the ergosterol synthesis pathway.

Systemic fungal infections: eradicates invasive pathogens such as Candida and Aspergillus species. Dermatophyte infections: clears skin, hair and nail infections caused by Trichophyton, Microsporum and Epidermophyton. Candida infections: treats oropharyngeal, esophageal and systemic candidiasis. Aspergillosis: controls chronic or invasive disease caused by Aspergillus spp.

Itraconazole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting: mild gastrointestinal upset. - Headache: transient cranial discomfort. - Diarrhea: loose stools, usually self‑limiting. - Abdominal pain: cramping or discomfort. - Rash: mild skin irritation. - Elevated liver enzymes: mild, reversible changes.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury requiring monitoring. - Congestive heart failure: fluid retention and reduced cardiac function. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Visual disturbances: blurred vision or photophobia. - Severe allergic reactions: anaphylaxis or angioedema. - QT prolongation: cardiac arrhythmia risk in susceptible patients.

Before initiating itraconazole therapy, consider patient‑specific factors and safety measures.

Liver function: assess baseline hepatic enzymes and monitor periodically. Cardiac status: avoid in patients with existing heart failure or uncontrolled arrhythmias. Drug interactions: review concomitant medications for CYP3A4 substrates or inhibitors. Pregnancy and lactation: evaluate risk‑benefit, as safety data are limited. Renal impairment: adjust dosing only under medical supervision. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Itraconazole interacts with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): markedly reduce itraconazole exposure. - Certain antiarrhythmics (e.g., quinidine, amiodarone): increase risk of cardiac toxicity. - HIV protease inhibitors (e.g., ritonavir): may cause unpredictable plasma levels.

Moderate Interactions (Monitor Closely): - Statins metabolized by CYP3A4 (e.g., simvastatin, lovastatin): risk of myopathy. - Oral anticoagulants (e.g., warfarin): may enhance anticoagulant effect. - Benzodiazepines (e.g., midazolam, triazolam): increased sedation. - Proton pump inhibitors: may affect absorption of itraconazole capsules. - Digoxin: potential increase in serum concentrations.